The Bio-Plex Pro™ RBM human, rat, and canine kidney toxicity panels enable early detection and characterization of kidney toxicity and injury during drug development.
Hercules, CA — March 9, 2013 — Bio-Rad Laboratories, Inc. announces the launch of its new Bio-Plex Pro RBM human, rat, and canine kidney toxicity panels at the 2013 Society of Toxicology (SOT) annual meeting in San Antonio, TX, March 10–14. Developed through a partnership with Myriad RBM, Inc., the multiplex immunoassays comprise a set of biomarkers that addresses the need for early detection and characterization of kidney toxicity and injury during drug development.
Acute kidney injury (AKI) is a potentially deadly condition frequently caused by kidney damage due to drug exposure, trauma, or blood loss during a medical procedure. In contrast, chronic kidney injury (CKI) results from long-term diseases such as diabetes, high blood pressure, or an inherited syndrome.
Protein biomarkers found in urine can signal early signs of kidney toxicity and injury and may provide additional information about the location and severity of damage. The Bio-Plex Pro RBM assays enable the detection of multiple biomarkers in a single sample, which may reveal damage within hours of kidney injury. This early detection will allow for more efficient drug testing in both preclinical and clinical research settings.
“The decades-old current clinical tests are not able to detect damage early enough, as evidenced by the fact that two-thirds of the kidney may be irreparably damaged once the traditional biomarkers become elevated,” said Dr. Dominic Eisinger, director of strategic development for Myriad RBM. “The Bio-Plex Pro RBM panels encompass the most sensitive early markers of kidney injury for preclinical and clinical studies.”
The toxicity panels contain six of the seven markers approved by the FDA and EMEA for use in preclinical kidney toxicity assessment. Included in these panels are several other markers relevant to kidney toxicity and damage research. The assays are offered as kits that include everything needed to run the assay.
“The Bio-Plex Pro RBM kidney toxicity assays will allow preclinical researchers to monitor biomarker profiles that may predict drug toxicity in the clinic,” said Chris Linnevers, Bio-Rad’s Bio-Plex global product manager. “They also enable clinical researchers to monitor both disease progression and kidney injury during drug trials, which ultimately leads to better-optimized treatment and improved patient care.”
Dr. Eisinger will give a talk on the new assays at the SOT annual meeting. His talk, “Multiplex detection of drug-induced kidney toxicity with new Bio-Plex Pro RBM assays,” will review the need for sensitive and robust assays to evaluate and diagnose kidney injury. Investigators involved in preclinical and clinical studies of drug safety will learn about the analytical validation of the kits, including their performance in kidney injury studies.
Additional benefits of the Bio-Plex Pro RBM assays include:
- High performance — offer robust quantification of multiple proteins in human, rat, and canine urine samples
- Consistent results — optimized for high precision and lot-to-lot reproducibility of sample measurements
- Simple workflow — formatted on magnetic beads for simplified plate processing and rapid results
The Bio-Plex Pro RBM kidney toxicity panels are compatible with Bio-Plex® MAGPIX™ instruments and Bio-Plex 100/200 and 3D instruments as well as all Luminex platforms and software.
For more information on Bio-Rad’s Bio-Plex product portfolio, please visit www.bio-rad.com/bioplex.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for more than 60 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,300 people globally and had revenues exceeding $2 billion in 2012. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
Bio-Plex Pro RBM kits are manufactured by Myriad RBM.
Myriad RBM is a trademark of Myriad RBM
Luminex is a trademark of Luminex Corporation.
For more information contact:
Brett Houser
Bio-Rad Laboratories, Inc.
510-741-5613
Brett_Houser@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com